Pacific Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PACB and other ETFs, options, and stocks.

About PACB

Pacific Biosciences of California, Inc. engages in the development, manufacture, and marketing of advanced sequencing solutions for genetic analysis. It operates through the following geographical segments: America, Europe, Middle East, and Africa, and Asia Pacific. 

CEO
Mark David van Oene
CEOMark David van Oene
Employees
485
Employees485
Headquarters
Menlo Park, California
HeadquartersMenlo Park, California
Founded
2000
Founded2000
Employees
485
Employees485

PACB Key Statistics

Market cap
346.32M
Market cap346.32M
Price-Earnings ratio
-2.64
Price-Earnings ratio-2.64
Dividend yield
Dividend yield
Average volume
7.07M
Average volume7.07M
High today
$1.17
High today$1.17
Low today
$1.07
Low today$1.07
Open price
$1.15
Open price$1.15
Volume
13.28M
Volume13.28M
52 Week high
$2.73
52 Week high$2.73
52 Week low
$1.07
52 Week low$1.07

Stock Snapshot

The current Pacific Biosciences(PACB) stock price is $1.12, with a market capitalization of 346.32M. The stock trades at a price-to-earnings (P/E) ratio of -2.64.

During the trading session on 2026-08-12, Pacific Biosciences(PACB) shares reached a daily high of $1.17 and a low of $1.07. At a current price of $1.12, the stock is +4.7% higher than the low and still -4.4% under the high.

Trading volume for Pacific Biosciences(PACB) stock has reached 13.28M, versus its average volume of 7.07M.

The stock's 52-week range extends from a low of $1.07 to a high of $2.73.

The stock's 52-week range extends from a low of $1.07 to a high of $2.73.

PACB News

Investing.com 1d
PacBio at Canaccord Genuity conference: clinical growth offsets transition pain - Investing.com

...

PacBio at Canaccord Genuity conference: clinical growth offsets transition pain - Investing.com
Simply Wall St 4d
Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. Price Target To US$2.29

It's been a sad week for Pacific Biosciences of California, Inc. ( ), who've watched their investment drop 15% to US$1.19 in the week since the company reported...

Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. Price Target To US$2.29
TipRanks 6d
Pacific Biosciences Earnings Call: Growth Amid Headwinds

Pacific Biosciences ((PACB)) has held its Q2 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock powerful investing tools...

Analyst ratings

57%

of 7 ratings
Buy
57.1%
Hold
28.6%
Sell
14.3%

More PACB News

Nasdaq 6d
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, reported an adjusted loss per share of 14 cents for the second quarter of 2026, wider t...

PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut
TipRanks 7d
PacBio CEO Christian Henry steps down, Mark Van Oene succeeds

PacBio (PACB) announced that its board of directors has appointed Mark Van Oene as president and CEO, effective August 5. Van Oene, who has served as COO, succe...

People also own

Based on the portfolios of people who own PACB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.